Enrollment in this study is required for patients whom an unlicensed cord blood unit (CBU) is determined to be the best transplant option. All participants in this access and distribution protocol must provide informed consent and, if applicable, assent. Patients will receive the cord blood unit(s) by way of infusion into one of the veins. Receiving the cord blood unit transplant and allowing your medical data to be collected are the procedures involved in this study.
The purpose of this study is to assess how well and how quickly blood counts return to normal after transplant in recipients at a multi-institution setting using cord blood units (CBUs) that are not FDA licensed. Participation in this study will last approximately 1 year after transplant.
? Disorders affecting the hematopoietic system that are inherited, acquired,
or result from myeloablative treatment
? Signed informed consent
? Pediatric and adult patients of any age
? Patients who are receiving only licensed CBUs are not permitted
? Cord blood transplant recipients at international transplant centers are not